Journal of global antimicrobial resistance · 2026
Genomic epidemiology of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in Mwanza, Tanzania.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Silago Vitus, Kidenya Benson R, Oravcova Katarina, Matthews Louise, Mtemisika Conjester I, Mshana Stephen E, Claus Heike, Seni Jeremiah
Аннотация
BACKGROUND: Extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) and Klebsiella pneumoniae (ESBL-KP) represent major clinical threats globally. Genomic epidemiological data remain scarce in low- and middle-income countries, limiting a comprehensive understanding of antimicrobial-resistant pathogen diversity and clonal distribution. The present study investigated the genomic epidemiology of ESBL-EC and ESBL-KP isolates in Mwanza, Tanzania.
METHODS: This cross-sectional hospital-based study employed whole-genome sequencing to characterise ESBL-EC (n = 39) and ESBL-KP (n = 49) isolated from patients with bloodstream, urinary tract, and wound infections at a zonal referral hospital between June 2019-June 2020 and March-August 2023.
RESULTS: Thirteen sequence types (STs) were identified among ESBL-EC, predominantly ST131 (30.7%) and ST648 (28.2%). ESBL-KP comprised 15 STs, with ST2390 (24.5%) and ST17 (18.4%) being the most common. The blaCTX-M-15 gene was detected in 87.2% of ESBL-EC and 95.9% of ESBL-KP. IncFII was the dominant plasmid replicon in ESBL-EC (63.9%) and ESBL-KP (83.7%), while repB was detected exclusively in ESBL-KP (28.6%), particularly among ST2390. ESBL-EC showed significantly higher resistance to ciprofloxacin (P < 0.01), whereas ESBL-KP demonstrated higher resistance to gentamicin and piperacillin-tazobactam (both P < 0.01). The cgMLST-based Neighbour-Joining phylogenetic analysis revealed substantial genetic diversity and identified clonal clusters involving the high-risk clone ESBL-EC ST131. Clusters of ESBL-EC ST131 and ST648 were observed across medical and neonatology wards, while ESBL-KP ST2390 clusters were mainly confined to neonatology wards.
CONCLUSION: This study highlights clonal clusters, the first report of ESBL-KP ST2390, and the predominance of the virulent high-risk clone ESBL-EC ST131 in Mwanza, Tanzania. Underscoring the critical need for reinforced infection control strategies and genomic surveillance.
METHODS: This cross-sectional hospital-based study employed whole-genome sequencing to characterise ESBL-EC (n = 39) and ESBL-KP (n = 49) isolated from patients with bloodstream, urinary tract, and wound infections at a zonal referral hospital between June 2019-June 2020 and March-August 2023.
RESULTS: Thirteen sequence types (STs) were identified among ESBL-EC, predominantly ST131 (30.7%) and ST648 (28.2%). ESBL-KP comprised 15 STs, with ST2390 (24.5%) and ST17 (18.4%) being the most common. The blaCTX-M-15 gene was detected in 87.2% of ESBL-EC and 95.9% of ESBL-KP. IncFII was the dominant plasmid replicon in ESBL-EC (63.9%) and ESBL-KP (83.7%), while repB was detected exclusively in ESBL-KP (28.6%), particularly among ST2390. ESBL-EC showed significantly higher resistance to ciprofloxacin (P < 0.01), whereas ESBL-KP demonstrated higher resistance to gentamicin and piperacillin-tazobactam (both P < 0.01). The cgMLST-based Neighbour-Joining phylogenetic analysis revealed substantial genetic diversity and identified clonal clusters involving the high-risk clone ESBL-EC ST131. Clusters of ESBL-EC ST131 and ST648 were observed across medical and neonatology wards, while ESBL-KP ST2390 clusters were mainly confined to neonatology wards.
CONCLUSION: This study highlights clonal clusters, the first report of ESBL-KP ST2390, and the predominance of the virulent high-risk clone ESBL-EC ST131 in Mwanza, Tanzania. Underscoring the critical need for reinforced infection control strategies and genomic surveillance.